Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 4/20 | 0.55 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.45 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.45 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880575 | 0.90 | HRH3 (0.50) | UBE2MDCUN1D1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3879089 | 0.90 | KDM4E (0.51) | UBE2MDCUN1D1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3880372 | 0.89 | L3MBTL3 (0.45) | UBE2MDCUN1D1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3880889 | 0.89 | UBE2M (0.59) | UBE2MDCUN1D1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3878546 | 0.87 | L3MBTL3 (0.43) | UBE2MDCUN1D1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3879400 | 0.87 | L3MBTL3 (0.40) | UBE2MDCUN1D1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3879014 | 0.87 | PROKR1 (0.44) | UBE2MDCUN1D1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3882382 | 0.87 | L3MBTL3 (0.44) | UBE2MDCUN1D1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3878937 | 0.85 | MAPT (0.45) | LMNAKMT2AMAPTCYP3A4CYP2C19 | |
| SCHEMBL3880220 | 0.84 | HSD11B1 (0.46) | UBE2MDCUN1D1L3MBTL3L3MBTL1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | claimed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | claimed |
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | UBE2M 4124/4885DCUN1D1 2343/4885L3MBTL3 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.